|
|
|
IBCSG 22-00
Low-dose cytotoxics as "anti-angiogenesis treatment" following adjuvant induction chemotherapy for patients with ER-negative and PgR-negative breast cancer
DESIGN
Serum Substudy
Assessment of Vascular Endothelial Growth Factor (VEGF), Soluble Her2 Protein (NRP, Neu-Related Protein), and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in serum samples.
|
|
Study ChairDr. Marco Colleoni - Milano, Italy
StatisticianShari Gelber
Trial CoordinatorsJoie Celano, Sandy Lippert, Meghan Metz, Kris Rickard, Cindy Westby
IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg22@fstrf.org
Date of ActivationNovember 22, 2000
Targeted Accrual900 patients
 Substudies
News
18.06.2010:
CMF chemotherapy is effective for triple-negative, node-negative breast cancer in IBCSG Trials VIII
05.05.2010:
A few impressions from our audits
27.01.2010:
First issue of SOLE flash, the short newsletter for IBCSG 35-07 SOLE
All News
|
|